Cevimeline hydrochloride

• CAT Number: I000332
• CAS Number: 107220-28-0
• Molecular Formula: C10H17NOS HCl
• Molecular Weight: 235.80
• Purity: ≥95%
• Synonyms: AF 102B;SNI 2011;SNK 508
• Target: Neuronal Signaling
• Solubility: Soluble to 75 mM in water and to 50 mM in DMSO
• Storage: -20°C
• IUPAC Name: (2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane];hydrochloride
• InChI: InChI=1S/C10H17NOS.ClH/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11;/h8-9H,2-7H2,1H3;1H/t8-,10-;/m1./s1
• InChIKey: SURWTGAXEIEOGY-GHXDPTCOSA-N
• SMILES: C[C@@H]1O[C@]2(CN3CCC2CC3)CS1.Cl

Cevimeline hydrochloride（Cat No.:I000332）is a medication primarily used to treat symptoms of dry mouth (xerostomia) in patients with Sjögren’s syndrome, an autoimmune disorder. It is a muscarinic receptor agonist, specifically targeting M3 receptors in the salivary glands, which stimulates saliva production. By enhancing salivation, cevimeline helps alleviate dryness and discomfort. It is taken orally and is generally well-tolerated, although side effects may include sweating, nausea, and headache. Cevimeline is marketed under the brand name Evoxac and is an alternative to other treatments like pilocarpine for dry mouth management.